Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convidecia Air in stable mild to moderate COPD population
ChiCTR2300073367Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 4 trial of ad5-ncov in coronavirus disease 2019 (COVID-19), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Incidence of acute exacerbation attacks, Day 28 SARS-CoV-2 neutralizing antibody response and 3 more. Started Dec 2022; status: recruiting.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300073367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073367.